Eli

The Danish pharmaceutical heavyweight is fighting on two legal fronts just days before a pivotal earnings report, with…

Novo Nordisk has started selling an oral version of its blockbuster obesity drug Wegovy to private patients in…

Novo Nordisk is fighting back on multiple fronts as its rival Eli Lilly tightens its grip on the…

Novo Nordisk is racing to defend its weight-loss empire on three continents simultaneously, rolling out the oral version…

Novo Nordisk’s shares have been hammered, losing roughly 46% over the past twelve months and trading at a…

Novo Nordisk’s shares are nursing a near-47% loss over the past year, and the latest clinical data did…

Novo Nordisk’s oral Wegovy pill notches 18,410 new US scripts in launch week, five times Eli Lilly’s Foundayo.…

EU recommends Novo’s oral semaglutide for weight loss, but Eli Lilly’s Retatrutide achieves 28.3% weight reduction in Phase…

Novo Nordisk’s oral Wegovy pill leads Eli Lilly’s Foundayo 2-to-1 in US prescriptions, but faces generic competition in…

Novo Nordisk shares jump 6.4% as oral Wegovy prescriptions dwarf Eli Lilly’s rival, while pivotal CagriSema trial data…

Novo Nordisk slashes U.S. drug prices up to 50% by 2027 and partners with OpenAI to counter Eli…

Novo Nordisk shares fall 50% from highs as Eli Lilly’s oral GLP-1 pill challenges Wegovy. The firm launches…

Novo Nordisk Faces a Legal Double Header as Earnings Approach